» Authors » Zerai Manna

Zerai Manna

Explore the profile of Zerai Manna including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 759
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakabo S, Sandoval-Heglund D, Hanata N, Brooks S, Hoffmann V, Zhang M, et al.
Front Immunol . 2024 Dec; 15:1465185. PMID: 39664388
Objectives: An important pathogenic role for neutrophils in systemic lupus erythematosus (SLE) has been proposed. Neutrophils that lack brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 (), one of...
2.
Patino-Martinez E, Nakabo S, Jiang K, Carmona-Rivera C, Tsai W, Claybaugh D, et al.
J Immunol . 2024 Jul; 213(4):419-434. PMID: 38949522
The Krebs cycle enzyme aconitate decarboxylase 1 (ACOD1) mediates itaconate synthesis in monocytes and macrophages. Previously, we reported that administration of 4-octyl itaconate to lupus-prone mice abrogated immune dysregulation and...
3.
Patino-Martinez E, Nakabo S, Jiang K, Carmona-Rivera C, Tsai W, Claybaugh D, et al.
medRxiv . 2024 Apr; PMID: 38605883
Objective: The Krebs cycle enzyme Aconitate Decarboxylase 1 (ACOD1) mediates itaconate synthesis in myeloid cells.. Previously, we reported that administration of 4-octyl itaconate abrogated lupus phenotype in mice. Here, we...
4.
Rossi G, Maggiore U, Peyronel F, Fenaroli P, Delsante M, Benigno G, et al.
Kidney Int Rep . 2022 Dec; 7(12):2647-2656. PMID: 36506236
Introduction: Proliferative lupus nephritis (LN) progresses to end-stage kidney disease (ESKD) in roughly 10% of the cases despite treatment. Other than achieving <0.8 g/24h proteinuria at 12 months after treatment,...
5.
Hasni S, Feng L, Chapman M, Gupta S, Ahmad A, Munday A, et al.
Lupus Sci Med . 2022 Oct; 9(1). PMID: 36220328
Objective: In patients with systemic lupus erythematosus (SLE), fatigue is a debilitating symptom with poorly understood pathophysiology. Cardiorespiratory dysfunction has been hypothesised as a contributor to SLE-fatigue. The purpose of...
6.
Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci P, et al.
Nat Commun . 2021 Jun; 12(1):3391. PMID: 34099646
Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models,...
7.
Sagar D, Gaddipati R, Ongstad E, Bhagroo N, An L, Wang J, et al.
PLoS One . 2020 Mar; 15(3):e0229184. PMID: 32182251
Traditional cardiovascular disease (CVD) risk factors, such as hypertension, dyslipidemia and diabetes do not explain the increased CVD burden in systemic lupus erythematosus (SLE). The oxidized-LDL receptor, LOX-1, is an...
8.
Smith M, Chiang C, Zerrouki K, Rahman S, White W, Streicher K, et al.
Sci Rep . 2020 Mar; 10(1):4462. PMID: 32157125
Type I interferon (IFN) drives pathology in systemic lupus erythematosus (SLE) and can be tracked via IFN-inducible transcripts in blood. Here, we examined whether measurement of circulating proteins, which enter...
9.
Mistry P, Nakabo S, ONeil L, Goel R, Jiang K, Carmona-Rivera C, et al.
Proc Natl Acad Sci U S A . 2019 Nov; 116(50):25222-25228. PMID: 31754025
Neutrophil dysregulation is implicated in the pathogenesis of systemic lupus erythematosus (SLE). SLE is characterized by elevated levels of a pathogenic neutrophil subset known as low-density granulocytes (LDGs). The origin...
10.
Purmalek M, Carlucci P, Dey A, Sampson M, Temesgen-Oyelakin Y, Sakhardande S, et al.
Lupus Sci Med . 2019 Aug; 6(1):e000332. PMID: 31413851
Objective: Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR...